Charles River to close ‘15 smaller sites’ as demand for early research declinesnews2024-11-08T16:28:38+00:00November 8th, 2024|Endpoints News|
Daiichi, Alteogen to work on subcutaneous Enhertu; Roche ends Nykode dealnews2024-11-08T16:08:40+00:00November 8th, 2024|Endpoints News|
BenevolentAI co-founder returns with plan to save drug developernews2024-11-08T14:00:41+00:00November 8th, 2024|Endpoints News|
Legend names a president of Carvykti; Novo Nordisk’s top North America exec is stepping downnews2024-11-08T12:00:54+00:00November 8th, 2024|Endpoints News|
Nkarta drops another cancer program as it leans into autoimmune diseasenews2024-11-08T11:59:06+00:00November 8th, 2024|Endpoints News|
Athira gives up on lead Alzheimer’s drug, switches tack to ALSnews2024-11-08T11:54:06+00:00November 8th, 2024|Endpoints News|
Pfizer to invest $1B in China over next five years — reportsnews2024-11-07T20:13:39+00:00November 7th, 2024|Endpoints News|
Senior AstraZeneca exec detained in China amid wider investigationnews2024-11-07T19:54:33+00:00November 7th, 2024|Endpoints News|
Stephen Squinto’s JPM life sciences team is raising a new fund for later-stage companiesnews2024-11-07T19:51:31+00:00November 7th, 2024|Endpoints News|
Vaccine makers face headwinds from RFK, soft demand and Chinanews2024-11-07T18:25:57+00:00November 7th, 2024|Endpoints News|
